期刊文献+

高效液相色谱法测定人血浆中伏立康唑浓度 被引量:16

Quantitation of human plasma voriconazole concentration by HPLC
下载PDF
导出
摘要 目的:建立一种快速、灵敏及检测范围广的高效液相色谱法测定人血浆中伏立康唑浓度的方法。方法:采用LC-10A(岛津)高效液相色谱仪,以尼群地平为内标,以Hypersil ODS柱(250mm×4.6mm,5μm)为分析柱;流动相为20mmol·L^-1磷酸二氢钾缓冲液(pH6.0)-乙腈(55:45);流速为1.0mL·min^-1;进样量为50μL;检测波长为254nm。血浆样品用乙腈沉淀蛋白,离心后取上清液进样分析。结果:色谱峰分离良好,无内源性杂质干扰。线性方程为:Y:0.3124X-0.0693,r=0.9991(0.2~20.0mg·L^-1);最低检测浓度为0.05mg·L^-1。平均方法回收率为94.6%~105.4%(n=15),日内、日间RSD≤9.2%。结论:本方法准确灵敏,操作简便、快速,适用于伏立康唑血药浓度的监测,也可用药动学研究。 OBJECTIVE To develop a HPLC method to determine the concentration of voriconazole in human plasma. METHODS A reversed phase C18 column (250 mm×4. 6 mm, 5μm) was used for the determination of voriconazole and nitrendipine (internal standard) with a mobile phase composed of 20 mmol·L^-1 phosphate buffer solution (pH 6. 0) - acetonitrile (55:45, v/v) at a flow rate of 1.0 mL·min^-1. The detector was operated at the 254 nm. Plasma samples were deposited down the protein with acetonitrile. RESULTS The chromatography was good and not interfered by the components of the plasma. Calibration curve was linear from 0. 2 to 20 mg L^-1. The recovery from rat plasma was 94. 6% -105.4% (n = 15). The limit of detection was 0. 05 mg·L^-1. The intra- and inter-day precision (C. V. ) was less than 9. 2%. CONCLUSION The method is accurate, sensitive and convenient, and is suitable for the determination of voriconazole concentration in human plasma and pharmacokinetic study.
作者 南志成
出处 《中国医院药学杂志》 CAS CSCD 北大核心 2006年第7期836-839,共4页 Chinese Journal of Hospital Pharmacy
关键词 伏立康唑 高效液相色谱法 血药浓度 抗真菌药 voriconazole HPLC plasma antifungal agent
  • 相关文献

参考文献7

  • 1姚斌,金永生,潘亚菊.伏立康唑拆分方法的改进[J].第二军医大学学报,2004,25(6):691-691. 被引量:4
  • 2沈海蓉 李中东 钟明康.氟康唑治疗细菌性感染的疗效观察[J].中国医院药学杂志,2004,23(5):308-310.
  • 3宋晓静,许冰.耐药念珠菌的研究进展[J].临床皮肤科杂志,2002,31(11):732-734. 被引量:3
  • 4丁鼎乐.美国上市新药销售额锐减[J].上海医药,2003,24(8):358-358.
  • 5Stopher DA,Gage R.Determination of a new antifungal a gent,voriconazole,by multidimensional high-performance liquid chromatography with direct plasma injection onto a size-exclusion column[J].J.Chromatogr.B,1997,691,441-448.
  • 6L.Zhou,R.D.Glickman,N.Chen,et al,Determination of voriconazole in aqueous humor by liquid chromatography electrospray ionization-mass spectrometry[J].J.Chromatogr.B,2002,776,213-220.
  • 7王晓玲.HPLC法测定抗真菌药伏立康唑的有关物质[J].西南民族大学学报(自然科学版),2004,30(5):595-597. 被引量:3

二级参考文献27

  • 1[1]Pfizer.Voriconazole[J]. Drugs Fut,2001,26(3):318-324.
  • 2[3]Pfizer Research and Development Company. Preparation of triazoles by organometallic addition to ketones and intermediates therefor[P]. WO Pat 97/06 1 60,1997-02-20.
  • 3[4]Ray SJ, Richardson K. Triazole antifungal agents[P]. US Pat 5278175,1994-01-11.
  • 4Sofia Perea, Gennethel J. Comparison of High-Performance Liquid Chromatographic and Microbiological Methods for Determination of voriconazole Levels in Plasma[J]. Antimicrobial Agents and Chemotherapy, 2000, 44(5): 1209-1213.
  • 5丁鼎乐.美国上市新药销售额锐减[J].上海医药,2003,24(8):358-358.
  • 6Graybill JR.Changing strategies for treatment of systemic mycoses[J]. Braz J Infect Dis, 2000, 4(2):47-54.
  • 7Magaldi S, Mata S, Haitung C,et al. In vitro susceptibility of 137 Candida spp. isolates from HIV positive patients to several antifungal drugs[J].Mycopathologia,2001,149(2):63-68.
  • 8Ng KP, Saw TL, Na SL, et al. Systemic Candida infection in U niversity hospital 1997-1999: the distribution of candida biotypes and antifungal susceptibility patterns[J]. Mycopathologia, 2001, 149 (3):141-146.
  • 9Pfaller MA, Jones RN, Doern GV,et al. Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997-1998[J]. Antimicrob A gents Chemother,2000,44(3):747-751.
  • 10Rocco TR, Reinert SE, Simms HH. Effects of fluconazole adminis tration in critically ill patients analysis of bacterial and fungal resistance[J]. Arch Surg,2000,135(2):160-165.

共引文献7

同被引文献2230

引证文献16

二级引证文献55

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部